Abstract
Background: Azilsartan medoxomil (AZM) is the newest representative in the class of angiotensin receptor blockers. Azilsartan medoxomil in combination with the older diuretic chlorthalidone (CLD) in fixed-doses of AZM/CLD 40/12.5 mg and 40/25 mg has been approved by the FDA for use in patients with essential hypertension. We sought to evaluate the safety and tolerability of AZL-M alone and in combination with CLD.
Methods: We conducted a search in PubMed using the keywords ‘azilsartan’, ‘azilsartan medoxomil’, ‘chlorthalidone, ‘safety’, ‘tolerability’ in order to find scientific studies evaluating the safety of these drugs. We included studies reporting side effects of these drugs, alone or in combination, in comparison to placebo or other antihypertensive medications. For our systematic review, we followed the PRISMA guidelines.
Results: Azilsartan medoxomil is a potent antihypertensive medicine with an acceptable safety profile. The most commonly reported adverse events are dizziness, headache, fatigue, upper respiratory tract infection and urinary tract infection. Chlorthalidone is more potent and has a considerably longer duration of action than the most commonly prescribed diuretic hydrochlorothiazide. Safety and tolerability between these two drugs are similar except higher serum uric acid and lower potassium levels with chlorthalidone.
Conclusion: The combination of azilsartan medoxomil with chlorthalidone has been shown to be effective in lowering blood pressure with an acceptable safety and tolerability profile. This fixeddose combination is an attractive treatment option for hypertension management.
Keywords: Genetics, hypertension, polymorphism, epigenomics, epidemiology, haplotypes.
Graphical Abstract
[1]
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-104.
[http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID: 30165516]
[http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID: 30165516]
[2]
Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept 2000; 93: 65-77.
[http://dx.doi.org/10.1016/S0167-0115(00)00178-6]
[http://dx.doi.org/10.1016/S0167-0115(00)00178-6]
[3]
Angeli F, Verdecchia P, Pascucci C, Poltronieri C, Reboldi G. Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension. Expert Opin Drug Metab Toxicol 2013; 9(3): 379-85.
[http://dx.doi.org/10.1517/17425255.2013.769521] [PMID: 23387516]
[http://dx.doi.org/10.1517/17425255.2013.769521] [PMID: 23387516]
[7]
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162(11): 777-84.
[http://dx.doi.org/10.7326/M14-2385] [PMID: 26030634]
[http://dx.doi.org/10.7326/M14-2385] [PMID: 26030634]
[8]
Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1.
[http://dx.doi.org/10.1186/2046-4053-4-1] [PMID: 25554246]
[http://dx.doi.org/10.1186/2046-4053-4-1] [PMID: 25554246]
[9]
Handley A, Lloyd E, Roberts A, Barger B. Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. Clin Exp Hypertens 2016; 38(2): 180-8.
[http://dx.doi.org/10.3109/10641963.2015.1081213] [PMID: 26817604]
[http://dx.doi.org/10.3109/10641963.2015.1081213] [PMID: 26817604]
[10]
Weber MA, Sever P, Juhasz A, Roberts A, Cao C. A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone. J Renin Angiotensin Aldosterone Syst 2018; 19(3): 1470320318795000.
[http://dx.doi.org/10.1177/1470320318795000] [PMID: 30175930]
[http://dx.doi.org/10.1177/1470320318795000] [PMID: 30175930]
[11]
Zaiken K, Cheng JW. Azilsartan medoxomil: a new Angiotensin receptor blocker. Clin Ther 2011; 33(11): 1577-89.
[http://dx.doi.org/10.1016/j.clinthera.2011.10.007] [PMID: 22071238]
[http://dx.doi.org/10.1016/j.clinthera.2011.10.007] [PMID: 22071238]
[12]
Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011; 13(2): 81-8.
[http://dx.doi.org/10.1111/j.1751-7176.2010.00425.x] [PMID: 21272195]
[http://dx.doi.org/10.1111/j.1751-7176.2010.00425.x] [PMID: 21272195]
[13]
White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57(3): 413-20.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.163402] [PMID: 21282560]
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.163402] [PMID: 21282560]
[14]
Shiga Y, Miura SI, Motozato K, et al. Comparison of Efficacy and Safety of Azilsartan and Olmesartan in Patients With Essential Hypertension. Int Heart J 2017; 58(3): 416-21.
[http://dx.doi.org/10.1536/ihj.16-285] [PMID: 28496022]
[http://dx.doi.org/10.1536/ihj.16-285] [PMID: 28496022]
[15]
Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2011; 13(7): 467-72.
[http://dx.doi.org/10.1111/j.1751-7176.2011.00482.x] [PMID: 21762358]
[http://dx.doi.org/10.1111/j.1751-7176.2011.00482.x] [PMID: 21762358]
[16]
Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012; 35(5): 552-8.
[http://dx.doi.org/10.1038/hr.2012.8] [PMID: 22278628]
[http://dx.doi.org/10.1038/hr.2012.8] [PMID: 22278628]
[17]
Bönner G, Bakris GL, Sica D, et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27(8): 479-86.
[http://dx.doi.org/10.1038/jhh.2013.6] [PMID: 23514842]
[http://dx.doi.org/10.1038/jhh.2013.6] [PMID: 23514842]
[18]
Gitt AK, Bramlage P, Potthoff SA, et al. Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. BMC Cardiovasc Disord 2016; 16: 56.
[http://dx.doi.org/10.1186/s12872-016-0222-6] [PMID: 26956148]
[http://dx.doi.org/10.1186/s12872-016-0222-6] [PMID: 26956148]
[19]
Kario K, Hoshide S. Age-related difference in the sleep pressure-lowering effect between an angiotensin II receptor blocker and a calcium channel blocker in Asian hypertensives: the ACS1 Study. Hypertension 2015; 65(4): 729-35.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.04935] [PMID: 25646296]
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.04935] [PMID: 25646296]
[20]
Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990; 82(5): 1616-28.
[http://dx.doi.org/10.1161/01.CIR.82.5.1616] [PMID: 2225366]
[http://dx.doi.org/10.1161/01.CIR.82.5.1616] [PMID: 2225366]
[21]
Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57(4): 689-94.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.161505] [PMID: 21383313]
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.161505] [PMID: 21383313]
[22]
Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47(3): 352-8.
[http://dx.doi.org/10.1161/01.HYP.0000203309.07140.d3] [PMID: 16432050]
[http://dx.doi.org/10.1161/01.HYP.0000203309.07140.d3] [PMID: 16432050]
[23]
Saseen JJ, Ghushchyan V, Nair KV. Comparing clinical effectiveness and drug toxicity with hydrochlorothiazide and chlorthalidone using two potency ratios in a managed care population. J Clin Hypertens (Greenwich) 2015; 17(2): 134-40.
[http://dx.doi.org/10.1111/jch.12453] [PMID: 25496048]
[http://dx.doi.org/10.1111/jch.12453] [PMID: 25496048]
[24]
Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59(6): 1104-9.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.190637] [PMID: 22547443]
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.190637] [PMID: 22547443]
[25]
Sica D, Bakris GL, White WB, et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) 2012; 14(5): 284-92.
[http://dx.doi.org/10.1111/j.1751-7176.2012.00616.x] [PMID: 22533654]
[http://dx.doi.org/10.1111/j.1751-7176.2012.00616.x] [PMID: 22533654]
[26]
Bakris GL, Sica D, White WB, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med 2012; 125(12): 1229.e1-1229.e10.
[http://dx.doi.org/10.1016/j.amjmed.2012.05.023] [PMID: 22939358]
[http://dx.doi.org/10.1016/j.amjmed.2012.05.023] [PMID: 22939358]
[27]
Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43(1): 4-9.
[http://dx.doi.org/10.1161/01.HYP.0000103632.19915.0E] [PMID: 14638621]
[http://dx.doi.org/10.1161/01.HYP.0000103632.19915.0E] [PMID: 14638621]
[28]
Collier DJ, Juhasz A, Agabiti-Rosei E, et al. Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trial. J Clin Hypertens (Greenwich) 2018; 20(10): 1473-84.
[http://dx.doi.org/10.1111/jch.13376] [PMID: 30302936]
[http://dx.doi.org/10.1111/jch.13376] [PMID: 30302936]
[29]
Kipnes MS, Handley A, Lloyd E, Barger B, Roberts A. Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension. J Clin Hypertens (Greenwich) 2015; 17(3): 183-92.
[http://dx.doi.org/10.1111/jch.12474] [PMID: 25619410]
[http://dx.doi.org/10.1111/jch.12474] [PMID: 25619410]
[30]
Cushman WC, Bakris GL, White WB, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension 2012; 60(2): 310-8.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.188284] [PMID: 22710649]
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.188284] [PMID: 22710649]
[31]
Neutel JM, Cushman WC, Lloyd E, Barger B, Handley A. Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide. J Clin Hypertens (Greenwich) 2017; 19(9): 874-83.
[http://dx.doi.org/10.1111/jch.13009] [PMID: 28681550]
[http://dx.doi.org/10.1111/jch.13009] [PMID: 28681550]
[32]
Bakris GL, Zhao L, Kupfer S, et al. Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. J Clin Hypertens (Greenwich) 2018; 20(4): 694-702.
[http://dx.doi.org/10.1111/jch.13230] [PMID: 29504252]
[http://dx.doi.org/10.1111/jch.13230] [PMID: 29504252]
Article Metrics
20
1